CRY - CryoLife, Inc.

NYSE - NYSE Delayed Price. Currency in USD

CryoLife, Inc.

1655 Roberts Boulevard NW
Kennesaw, GA 30144
United States

IndustryMedical Appliances & Equipment
Full Time Employees665

Key Executives

Mr. James Patrick MackinChairman, CEO & Pres1.23MN/A50
Mr. David Ashley Lee CPAExec. VP, COO & CFO716k452.79k52
Ms. Jean F. Holloway Esq.Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.526.04k22.16k60
Mr. John E. DavisSr. VP of Global Sales & Marketing519.16kN/A52
Mr. William Robert MatthewsSr. VP of Operations, Quality and Regulatory541.52kN/A62
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CryoLife, Inc., together with its subsidiaries, manufactures and distributes medical devices worldwide. It also processes and distributes implantable human tissues for use in cardiac and vascular surgeries. The company operates in two segments, Medical Devices and Preservation Services. It offers surgical sealants and hemostats, including BioGlue Surgical Adhesive, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; BioFoam Surgical Matrix, which is used as an adjunct in sealing abdominal parenchymal tissues, as well as an adjunct for hemostasis in cardiovascular surgery; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser console system and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina; and On-X heart valves for aortic and mitral indications. In addition, it distributes ProCol vascular bioprosthesis, a biological graft that provides vascular access for end-stage renal disease in hemodialysis patients; and PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities. Further, it distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using its proprietary SynerGraft technology; and vascular preservation services, such as CryoVein and CryoArtery tissues to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Corporate Governance

CryoLife, Inc.’s ISS Governance QualityScore as of November 1, 2017 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.